search
Back to results

Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE] (SAMOF-TPE)

Primary Purpose

Sepsis

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Therapeutic plasma exchange
Sponsored by
Forsyth Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients are eligible for inclusion if they have sepsis with refractory shock and evidence of organ failure.

Exclusion Criteria:

  • Persons who are pregnant
  • Persons who are incarcerated
  • Acute surgical catastrophe without potential for intervention or source control
  • Cardiac arrest with unknown neurologic status, including patients being treated with therapeutic hypothermia
  • Presence of severe acute brain injury or severe dementia
  • Cardiogenic, neurogenic, obstructive, or post-cardiotomy shock
  • Acute pancreatitis with no established source of infection
  • Diabetic ketoacidosis as primary pathology

    • Note: Septic patients who develop DKA are eligible for inclusion. However, patients in whom organ dysfunction and hemodynamic instability are due primarily to volume depletion and acidosis from DKA should not be included.
  • Need for mechanical circulatory support
  • Prolonged acute illness with > 24 hours of pressor needs at enrollment and/or end organ damage with further care deemed to be "futile."

    • NOTE: The time resets if a new inciting event leads to SAMOF.
    • For example, if a patient has sepsis stabilized but requires operative intervention for source control within the initial 24 hours of admission and returns to the ICU with SAMOF, the patient is again eligible for randomization for the next 24 hours.
  • Bedbound state or poor baseline functional status with ECOG performance status score ≥ 3
  • Underlying terminal illness/malignancy with < 6 months life expectancy
  • Advanced chronic liver disease/cirrhosis with evidence of portal hypertension
  • Asplenia
  • HIV with HARRT non-compliance

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Therapeutic plasma exchange

    Standard care alone for sepsis

    Arm Description

    Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure

    Standard care for patients with sepsis induced multi-organ failure

    Outcomes

    Primary Outcome Measures

    28-Day Mortality
    28 days

    Secondary Outcome Measures

    Full Information

    First Posted
    February 15, 2019
    Last Updated
    February 15, 2019
    Sponsor
    Forsyth Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03844542
    Brief Title
    Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]
    Acronym
    SAMOF-TPE
    Official Title
    Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    June 2019 (Anticipated)
    Primary Completion Date
    December 2022 (Anticipated)
    Study Completion Date
    June 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Forsyth Medical Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes

    5. Study Description

    Brief Summary
    The investigators prospective, randomized adult clinical trial investigates the therapeutic efficacy of early therapeutic plasma exchange as adjunct treatment to standard therapy in patients with refractory septic shock and multiple organ failure.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Sepsis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    300 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Therapeutic plasma exchange
    Arm Type
    Experimental
    Arm Description
    Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
    Arm Title
    Standard care alone for sepsis
    Arm Type
    No Intervention
    Arm Description
    Standard care for patients with sepsis induced multi-organ failure
    Intervention Type
    Device
    Intervention Name(s)
    Therapeutic plasma exchange
    Intervention Description
    Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
    Primary Outcome Measure Information:
    Title
    28-Day Mortality
    Description
    28 days
    Time Frame
    28 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult patients are eligible for inclusion if they have sepsis with refractory shock and evidence of organ failure. Exclusion Criteria: Persons who are pregnant Persons who are incarcerated Acute surgical catastrophe without potential for intervention or source control Cardiac arrest with unknown neurologic status, including patients being treated with therapeutic hypothermia Presence of severe acute brain injury or severe dementia Cardiogenic, neurogenic, obstructive, or post-cardiotomy shock Acute pancreatitis with no established source of infection Diabetic ketoacidosis as primary pathology Note: Septic patients who develop DKA are eligible for inclusion. However, patients in whom organ dysfunction and hemodynamic instability are due primarily to volume depletion and acidosis from DKA should not be included. Need for mechanical circulatory support Prolonged acute illness with > 24 hours of pressor needs at enrollment and/or end organ damage with further care deemed to be "futile." NOTE: The time resets if a new inciting event leads to SAMOF. For example, if a patient has sepsis stabilized but requires operative intervention for source control within the initial 24 hours of admission and returns to the ICU with SAMOF, the patient is again eligible for randomization for the next 24 hours. Bedbound state or poor baseline functional status with ECOG performance status score ≥ 3 Underlying terminal illness/malignancy with < 6 months life expectancy Advanced chronic liver disease/cirrhosis with evidence of portal hypertension Asplenia HIV with HARRT non-compliance
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Philip Keith, MD
    Phone
    843.693.0412
    Email
    pkeith@salemchest.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jeremy Hodges, RPh
    Phone
    336.718.8729
    Email
    jlhodges@novanthealth.org

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]

    We'll reach out to this number within 24 hrs